海通国际发布研报称，石药集团(01093)的主营业务收入、利润已经触底，2026年有望回到上升周期， 2027年开始受益于肿瘤和代谢创新产品放量，成药收入有望提速。石药集团当前潜在临床里程碑收入达 58亿美元(约人民币406亿元)，有望在未来3-5年陆续增厚公司利润。该行认为首付款和里程碑收入将为 公司带来可持续的经常性收益，并上调了2027年后的授权收入预测。该行使用现金流折现(DCF)模型及 FY27-FY35的现金流进行估值。基于WACC7.9%，永续增长率2.5%(均不变)，对应目标价13.07港元，并 维持"优于大市"评级。 海通国际主要观点如下： 研发能力多次获得认可，该行看好常态化里程碑收入夯实公司基本面 近两年来石药集团实现7笔对外合作交易，涉及首付款总额17.1亿美元，潜在里程碑总额超300亿美元。 公司与全球顶尖药企阿斯利康三度达成合作，彰显石药集团研发平台在全球范围的影响力与价值。该行 认为，加总近60亿美元的潜在研发里程碑将会在未来3-5年陆续增厚石药集团的利润，成为公司常态化 收入的重要组成部分。该行看好石药集团可以持续以销售里程碑和销售净额分成的方式在整个药品生命 周期分享经济效益 ...

研究报告 Research Report 25 Feb 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 跨国药企多次认可，创新转型成果凸显，平台价值值得期待 Multiple Recognitions from MNCs, Clear Progress in Innovation Transformation, Platform Value Highly Anticipated [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.06 目标价 HK$13.07 HTI ESG 3.0-2.5-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$115.92bn / US$14.82bn 日交易额 (3 个月均值) US$140.76mn 发行股票数目 11,522mn 自由流通股 (%) 68% 1 年股价最高最低值 HK ...

Core Insights - Investing in pharmaceutical stocks involves significant risks due to the lengthy and costly drug development process, which averages over 10 years and costs approximately $2.6 billion [1][2] Company Analysis - Eli Lilly is highlighted as a strong investment opportunity due to its robust drug pipeline and recent strategic acquisitions [4] - The company recently announced a $2.4 billion acquisition of Orna Therapeutics, which is focused on innovative gene and cell manipulation therapies [5] - Additionally, Lilly is collaborating with a Chinese biotechnology firm for $350 million to develop treatments for immune disorders and cancer, and has a billion-dollar deal with a German company for hearing-loss gene therapies [6] - Lilly's best-selling drug, tirzepatide, has surpassed Merck's Keytruda, making it the top-selling drug globally, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss [7] - Over the past five years, Lilly's shares have increased by more than 400%, significantly outperforming the S&P 500, which rose about 73% during the same period [8] - With a market capitalization of approximately $936 billion, Lilly is nearing the $1 trillion market cap milestone, a threshold currently held by only 12 public companies [8]

Core Insights - Eli Lilly is actively pursuing strategic acquisitions to enhance its long-term growth potential in the pharmaceutical industry [1][5][8] Company Overview - Eli Lilly's current market capitalization is $983 billion, with a gross margin of 83.04% and a dividend yield of 0.74% [6][7] - The company has established itself as a leader in the GLP-1 drug category, which is effective in lowering blood sugar levels and promoting weight loss [7] Recent Developments - Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics, which focuses on innovative gene and cell manipulation therapies [8] - Prior to the Orna acquisition, Lilly committed $350 million to collaborate with a Chinese biotech firm for immune disorder and cancer treatments, and also made a billion-dollar deal with a German company for hearing loss gene therapies [9] Industry Context - The pharmaceutical industry is characterized by volatile demand for drugs and challenges related to patent expirations, which can lead to market share loss to generic competitors [2][3] - Companies must continuously innovate and fill their pipelines with new drugs to sustain long-term growth [5]

Group 1: Company Performance - Eli Lilly has emerged as a leader in the GLP-1 drug category, particularly with its medication tirzepatide, which effectively lowers blood sugar and promotes weight loss [1] - Tirzepatide became the best-selling drug globally last year, surpassing Merck's Keytruda, and is marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss [2] - Sales of tirzepatide have driven Eli Lilly's stock price up by 400% over the past five years, although the stock has seen a decline of about 4% in 2026 [2] Group 2: Recent Acquisitions and Developments - Eli Lilly announced the acquisition of Orna Therapeutics for $2.4 billion, which is developing innovative gene therapies using circular RNA technology [3] - Orna's therapy, ORN-252, aims to enable the patient's body to generate necessary changes to combat diseases, representing a shift from traditional lab-modified treatments [4] - The new therapy is described as "clinical trial-ready," but commercial sales may still be several years away due to the lengthy drug development process [5] Group 3: Pipeline Expansion - In addition to the Orna acquisition, Eli Lilly is actively expanding its pipeline, including a $350 million collaboration with a Chinese biotech firm for immune disorder and cancer treatments [6] - The company also announced a billion-dollar deal with a German firm to develop gene therapies for hearing loss [6]

Core Insights - Eli Lilly (LLY) has entered into a definitive agreement to acquire Orna Therapeutics for $2.4 billion, which includes both upfront and milestone-based payments [1][8] - The acquisition will enhance Eli Lilly's portfolio with Orna's in vivo CAR-T pipeline, particularly the lead asset ORN-252, aimed at treating B-cell-driven autoimmune diseases [2][8] - Eli Lilly will also gain access to Orna's proprietary circular RNA platform, which may enable new therapeutic applications [3][8] Financial Performance - Eli Lilly's financial performance is currently strong, bolstered by the success of its GLP-1 therapies, Mounjaro and Zepbound, contributing to its market capitalization reaching $1 trillion [9][10] - The acquisition of Orna Therapeutics is seen as a long-term strategy for pipeline diversification rather than a response to immediate revenue pressures [10] Strategic Fit - The deal aligns with Eli Lilly's intent to diversify its therapeutic areas beyond metabolic diseases, as evidenced by recent regulatory approvals in immunology, oncology, and neuroscience [10] - Orna Therapeutics benefits from the acquisition as it lacks the commercial infrastructure to bring its advanced therapies to market, which Eli Lilly can provide [11] Recent M&A Activity - This acquisition marks Eli Lilly's second deal in 2023, following its offer to acquire Ventyx Biosciences for $1.2 billion, aimed at enhancing its portfolio in oral small-molecule therapies for inflammatory-mediated diseases [12]

Group 1 - US stock index futures showed slight increases, with Nasdaq futures up 0.22%, S&P 500 futures up 0.15%, and Dow futures up 0.01% [1] - European stock indices had mixed results, with Germany's DAX up 0.03%, UK's FTSE 100 down 0.34%, France's CAC up 0.25%, and the Euro Stoxx 50 up 0.19% [1] - Citigroup warned that "AI disruption" could lead software stocks to retest their 2023 lows, with a potential long-term terminal value evaporation of about one-third [1] - AI startup Anthropic plans to secure 10 gigawatts of data center computing power, surpassing OpenAI [1] - The US plans to exempt companies like Amazon, Google, and Microsoft from upcoming chip tariffs, potentially linked to TSMC's investment commitments [1] - TSMC reported a 36.8% year-on-year increase in January sales to a record high of NT$401.26 billion, with a board-approved capital budget of $44.962 billion [1] - Amazon plans to launch a content trading platform allowing publishers to sell content to AI companies [1] - Alphabet's Waymo achieved fully autonomous driving operations in Nashville, Tennessee [1] - Tesla's North American sales head Raj Jegannathan has left the company amid challenges of declining global demand [1] - Salesforce reportedly laid off fewer than 1,000 employees earlier this month, affecting marketing and product management roles [1] Group 2 - Eli Lilly will acquire Orna Therapeutics for $2.4 billion to strengthen its position in the autoimmune sector [2] - Baidu is reportedly secretly launching the "O Plan," which insiders say is related to the Baidu app [2] - Qianwen APP is testing integration with Damai, covering the entire process from film recommendations to payment and ticket issuance [2] - AstraZeneca expects a 9% increase in product sales to over $55.5 billion by 2025, anticipating continued growth this year [2] - Coca-Cola's Q4 net revenue of $11.8 billion fell short of expectations, with an anticipated adjusted organic revenue growth of 4-5% this year [2] - BP's Q4 underlying replacement cost profit increased by 32% year-on-year to $1.54 billion, with stock buybacks paused [2] - Barclays reported a pre-tax profit of £1.9 billion in Q4, exceeding expectations, and committed to returning at least £15 billion to shareholders by 2028 [2] - ON Semiconductor's Q4 revenue declined by 11% year-on-year to approximately $1.53 billion, with first-quarter guidance falling short of expectations [2] - Ferrari's Q4 net profit of €381 million exceeded expectations, with orders already booked through the end of 2027 [2]

Group 1 - Dow futures rose by 0.09%, S&P 500 futures increased by 0.10%, and Nasdaq futures gained 0.07% [1] - Philips reported Q4 2025 earnings with a 1% year-over-year sales increase to €5.1 billion and an adjusted EBITA of €770 million, exceeding market expectations, leading to a 6.89% stock increase [2] - Cisco launched a new AI network chip, "Silicon One G300," expected to enhance AI computing task speeds by 28%, utilizing TSMC's 3nm process technology [2] Group 2 - Alphabet, Google's parent company, initiated its first issuance of Swiss franc bonds and British pound bonds, with maturities ranging from 3 to 100 years [2] - TSMC reported January sales of NT$401.26 billion, a 36.8% year-over-year increase and a 19.8% month-over-month rise, leading to a 3.09% stock increase [2] - BP's Q4 earnings showed a benchmark replacement cost profit of $1.54 billion, aligning with analyst expectations, but the full-year net profit of $7.49 billion fell short of the $7.58 billion forecast, resulting in a 4.9% stock decline [2] Group 3 - AstraZeneca's 2025 total revenue reached $58.739 billion, an 8% year-over-year increase, with growth in biopharmaceuticals, oncology, and rare diseases, and plans for significant investment in China [3] - AppLovin's stock rose by 3.5% after a short-seller retracted allegations against a major shareholder, ensuring the protection of legal rights [3] Group 4 - Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics to gain CAR-T therapy technology, aiming to produce cells in vivo rather than in the lab [4] Group 5 - Optical communication stocks saw a pre-market surge, with Redo Technology up over 17%, Astera Labs rising over 5%, and Corning increasing by over 1% [5]

Group 1 - The core viewpoint of the article is that Eli Lilly announced its intention to acquire biotechnology company Orna Therapeutics for up to $2.4 billion in cash to strengthen its position in the autoimmune sector [1] Group 2 - Orna Therapeutics' main candidate drug, ORN-252, is aimed at treating B cell-driven autoimmune diseases and is currently in the early stages of development [1]

Core Viewpoint - Eli Lilly announced the acquisition of biotechnology company Orna Therapeutics for up to $2.4 billion in cash, focusing on the development of ORN-252, a candidate drug aimed at treating B cell-driven autoimmune diseases currently in early-stage development [1] Group 1 - Eli Lilly is acquiring Orna Therapeutics for a total cash consideration of up to $2.4 billion [1] - Orna Therapeutics' main candidate drug, ORN-252, targets B cell-driven autoimmune diseases [1] - The drug ORN-252 is currently in the early stages of development [1]